Overview

Safety and Efficacy of Nonacog Beta Pegol (N9-GP) in Previously Untreated Patients With Haemophilia B

Status:
Active, not recruiting
Trial end date:
2022-10-30
Target enrollment:
Participant gender:
Summary
This trial is conducted globally. The aim of the trial is to investigate the safety and efficacy of nonacog beta pegol (N9-GP) in previously untreated patients with Haemophilia B.
Phase:
Phase 3
Details
Lead Sponsor:
Novo Nordisk A/S